Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NASDAQ:CDMO - Avid Bioservices Stock Price, Forecast & News

$6.53
0.00 (0.00 %)
(As of 01/20/2020 03:19 AM ET)
Today's Range
$6.45
Now: $6.53
$6.74
50-Day Range
$5.34
MA: $6.91
$8.15
52-Week Range
$3.37
Now: $6.53
$8.38
Volume202,828 shs
Average Volume347,348 shs
Market Capitalization$367.90 million
P/E RatioN/A
Dividend YieldN/A
Beta2.78
Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.60 million
Book Value$0.95 per share

Profitability

Net Income$-4,220,000.00

Miscellaneous

Employees185
Market Cap$367.90 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices Inc (NASDAQ:CDMO) announced its quarterly earnings results on Monday, December, 9th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. The biopharmaceutical company earned $18.31 million during the quarter, compared to the consensus estimate of $14.34 million. Avid Bioservices had a negative return on equity of 8.78% and a negative net margin of 6.83%. The firm's quarterly revenue was up 79.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.05) earnings per share. View Avid Bioservices' Earnings History.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Avid Bioservices.

What price target have analysts set for CDMO?

5 equities research analysts have issued twelve-month price objectives for Avid Bioservices' shares. Their forecasts range from $7.50 to $11.00. On average, they anticipate Avid Bioservices' share price to reach $9.90 in the next year. This suggests a possible upside of 51.6% from the stock's current price. View Analyst Price Targets for Avid Bioservices.

What is the consensus analysts' recommendation for Avid Bioservices?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.

What are Wall Street analysts saying about Avid Bioservices stock?

Here are some recent quotes from research analysts about Avid Bioservices stock:
  • 1. According to Zacks Investment Research, "Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States. " (11/12/2019)
  • 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating with a price target of $11. Our valuation is based on a discounted EBITDA model, which we believe takes into account both the established and anticipated revenue growth of Avid, which is the cornerstone of the company’s business. We assign a 23x multiple on F2023 EBIDTA discounted back at Avid’s WACC of 13%." (7/8/2019)

Has Avid Bioservices been receiving favorable news coverage?

Media headlines about CDMO stock have trended negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avid Bioservices earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Avid Bioservices.

Who are some of Avid Bioservices' key competitors?

What other stocks do shareholders of Avid Bioservices own?

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the folowing people:
  • Dr. Roger J. Lias, Pres, CEO & Director (Age 59)
  • Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 46)
  • Mr. Stephen Michael Hedberg, Sr. Director of Fin. & SEC Reporting and Principal Financial & Accounting Officer (Age 44)
  • Ms. Lorna Larson, Sr. Director of HR

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $6.53.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $367.90 million and generates $53.60 million in revenue each year. The biopharmaceutical company earns $-4,220,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Avid Bioservices employs 185 workers across the globe.View Additional Information About Avid Bioservices.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is http://www.avidbio.com/.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]


MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  613
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel